---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-278012"
form_type: "8-K/A"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:03:10.923091+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Globus Medical files pro forma financials for NuVasive Merger; combined net income $6M for 9 months

## Summary
- Pro forma net income for nine months ended Sep 30, 2023: $6.0M ($0.04 diluted EPS) vs Globus standalone $107.8M.
- Total purchase price $2.6B; goodwill $924M, intangible assets $1.22B (developed tech, customer relationships).
- Pro forma net income for FY2022: $5.2M ($0.04 diluted EPS) vs Globus standalone $190.2M.
- NuVasive contributed $827M revenue for Jan–Aug 2023; inventory step-up of $284M added to cost of sales.

## SEC filing metadata
- accession: 0001193125-23-278012
- form_type: 8-K/A
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000119312523278012/0001193125-23-278012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000119312523278012/d315801d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-278012
- JSON: https://secwatch.observer/filing/0001193125-23-278012.json
- Plain text: https://secwatch.observer/filing/0001193125-23-278012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.